Anebulo Pharmaceuticals, Inc.
NASDAQ:ANEB
1.6 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Anebulo Pharmaceuticals, Inc. |
Symbool | ANEB |
Munteenheid | USD |
Prijs | 1.596 |
Beurswaarde | 41,376,421 |
Dividendpercentage | 0% |
52-weken bereik | 0.8 - 3.3 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Joseph F. Lawler M.D., Ph.D. |
Website | https://www.anebulo.com |
An error occurred while fetching data.
Over Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)